Stock Quote

Biogen Idec Inc. (BIIB.O) (Nasdaq)
As of  24 Nov 2009
47.38USD
Price Change
+0.59
Percent Change
+1.26%
 
$47.38
24 Nov 2009
+1.26%
$46.79
$47.01
3,118,789
$47.49
$46.79
$55.34
$39.01
0.60
3,579,987

Research Another Stock: Symbol Look-up
A Big Upgrade for Allos Therapeutics
Monday, 23 Nov 2009 04:12am EST(The Motley Fool) 
Spectrum Pharma: Zevalin Sales Ramp Up
Sunday, 22 Nov 2009 08:32am EST(Seeking Alpha) 
This Stock Is a Train Wreck
Thursday, 19 Nov 2009 10:17am EST(The Motley Fool) 
Genzyme's Termeer: Worst Biotech CEO of '09
Tuesday, 17 Nov 2009 12:31pm EST(The Street) 
Abbott: Brave or Stupid?
Friday, 13 Nov 2009 10:45am EST(The Motley Fool) 
 
Name Current Position Compensation
Ross, Bruce Non-Executive Chairman of the Board --
Mullen, James President, Chief Executive Officer, Director 8,970,980
Clancy, Paul Chief Financial Officer, Executive Vice President - Finance 1,363,070

Profile

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company’s products address diseases such as multiple sclerosis, non-Hodgkin’s lymphoma (NHL), rheumatoid arthritis (RA), crohn’s disease (CD) and psoriasis. The Company has four products: AVONEX... Full Description

Company Address

Biogen Idec Inc.
14 Cambridge Center
Cambridge   MA   02142
P: +1617.6792000
F: +1617.6792617

Analyst Research

Performance of Key Competitors

Company Price Change
Pfizer Inc. $18.31 -0.22
Novartis AG CHF55.60 +0.45
Teva Pharmaceutical Industries Limited ₪20,300.00 +140.00
  BIIB.O Industry
P/E(TTM) 15.65 12.99
P/S(TTM) 3.13 30.44
ROI(TTM) 11.10 2.46
ROE(TTM) 14.10 3.74
Consensus Recommendation Hold
EPS Est. (Current Period) 1.08
EPS Est. (Current Year) 3.98
Total Revenue $1,120.52M
Net Income $279.60M
EPS $0.95